Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Recurrent Uterine Leiomyosarcoma
NCT00378911Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2006
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in uterine leiomyosarcoma (uLMS), sponsored by National Cancer Institute. Primary endpoints: Progression-Free Survival Rate at 6 months, Objective Tumor Response up to 5 years and 1 more. Started Oct 2006; status: completed.
02
Drugs
sunitinib
03
Conditions
uterine leiomyosarcoma (uLMS)
Beyond the preview
Go deeper on NCT00378911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00378911.